<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770155</url>
  </required_header>
  <id_info>
    <org_study_id>2P20GM104357-08</org_study_id>
    <nct_id>NCT04770155</nct_id>
  </id_info>
  <brief_title>Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1</brief_title>
  <acronym>UMMC_Pilot</acronym>
  <official_title>Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research aims of this proposal are:&#xD;
&#xD;
        -  Specific Aim 1: To test whether an increase in nitric oxide signaling can increase&#xD;
           vasodilator responses in young Black individuals.&#xD;
&#xD;
        -  Specific Aim 2: To test whether a decrease in endothelin-1 signaling can increase&#xD;
           vasodilator responses in young Black individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies will be conducted in the Clinical Research and Trials Unit at the University of&#xD;
      Mississippi Medical Center. All study visits will follow the same procedures, except for the&#xD;
      drug or supplement being administered.&#xD;
&#xD;
      For Aim 1, double-blind, randomized, placebo-controlled crossover designs will examine the&#xD;
      effects of increasing nitric oxide and cyclic guanosine monophosphate bioavailability on&#xD;
      vascular function of young Black and White individuals. Three sets of two visits will be&#xD;
      performed:&#xD;
&#xD;
        -  Aim 1a: At the beginning of each visit, participants will ingest either a nitrate-rich&#xD;
           beetroot juice or a nitrate-depleted beetroot juice (serving as placebo) in their liquid&#xD;
           commercial form, which has a distinct color and flavor. The nitrates will be absorbed&#xD;
           and reduced in the plasma to nitrite and nitric oxide, increasing&#xD;
           endothelium-independent nitric oxide bioavailability.&#xD;
&#xD;
        -  Aim 1b: Participants will receive a 7-day supplement of L-citrulline or placebo before&#xD;
           each study visit, with a washout period of 7 days between visits. The activity of the&#xD;
           endothelial nitric oxide synthase converts L-arginine into nitric oxide and&#xD;
           L-citrulline, which is normally recycled back into L-arginine. Unlike L-arginine, oral&#xD;
           ingestion of L-citrulline is not catabolized in the gut, nor is it extracted from&#xD;
           systemic circulation through hepatic first-pass metabolism. Thus, ingested L-citrulline&#xD;
           becomes available in large quantities in the plasma for enzymatic conversion into&#xD;
           L-arginine, increasing endothelium-dependent nitric oxide bioavailability.&#xD;
&#xD;
        -  Aim 1c: At the beginning of each visit, participants will ingest a liquid mixture&#xD;
           prepared by Investigational Drug Services at the University of Mississippi Medical&#xD;
           Center containing Sildenafil or placebo. Sildenafil inhibits phosphodiesterase 5, an&#xD;
           enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells&#xD;
           inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the&#xD;
           availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated&#xD;
           intracellular cascade.&#xD;
&#xD;
      For Aim 2, a double-blind, randomized, placebo-controlled crossover design will examine the&#xD;
      role of endothelin-1 on the vascular function of young Black and White individuals. Two&#xD;
      visits will be performed, with a minimum of 7 days between them.&#xD;
&#xD;
      â€¢ Aim 2: At the beginning of each visit, participants will ingest a liquid mixture prepared&#xD;
      by Investigational Drug Services at the University of Mississippi Medical Center containing&#xD;
      Bosentan or placebo. Bosentan blocks ETA and ETB receptors, leading to a reduction in&#xD;
      vasoconstrictor tone and a greater magnitude of vasodilator responses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation</measure>
    <time_frame>Within 4 hours of drug/supplement administration.</time_frame>
    <description>The percent change in arterial diameter normalized to arterial shear rate during reperfusion after 5 minutes of circulatory occlusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactive hyperemia (cuff release)</measure>
    <time_frame>Within 4 hours of drug/supplement administration.</time_frame>
    <description>Blood velocity area-under-the-curve from the beginning of reperfusion to return to resting values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle hyperemia (passive leg movement)</measure>
    <time_frame>Within 4 hours of drug/supplement administration.</time_frame>
    <description>Peak and the area-under-the-curve of the change in femoral artery blood flow during 1 minute of passive leg movement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle hyperemia (rhythmic handgrip exercise)</measure>
    <time_frame>Within 4 hours of drug/supplement administration.</time_frame>
    <description>Changes in brachial artery blood flow and conductance during 3 minutes of rhythmic handgrip exercise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle hyperemia (rhythmic knee extension exercise)</measure>
    <time_frame>Within 4 hours of drug/supplement administration.</time_frame>
    <description>Changes in femoral artery blood flow and conductance during 3 minutes of rhythmic knee extension exercise.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vascular Function</condition>
  <condition>Racial Disparity</condition>
  <arm_group>
    <arm_group_label>Beetroot juice (Aim 1a)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a high (~12.8 mmol) concentration of nitrates (James White Drinks, Suffolk, UK).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Aim 1a)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a low concentration (~0.0055 mmol) of nitrates (James White Drinks, Suffolk, UK).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-citrulline (Aim 1b)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive pills containing 3 g of L-citrulline (Superior Labs, Park City, UT) to take twice daily for 7 days before the study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Aim 1b)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive pills containing a placebo to take twice daily for 7 days before the study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil (Aim 1c)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Upon arriving at the laboratory, participants will ingest a liquid mixture containing Sildenafil (100 mg), an inhibitor of phosphodiesterase 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Aim 1c)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bosentan (Aim 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Upon arriving at the laboratory, participants will ingest a liquid mixture containing Bosentan (125 mg), a non-selective blocker of endothelin-1 receptors ETA and ETB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Aim 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Nitrates 400 mg</intervention_name>
    <description>The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.</description>
    <arm_group_label>Beetroot juice (Aim 1a)</arm_group_label>
    <arm_group_label>Placebo (Aim 1a)</arm_group_label>
    <other_name>Beet It Sport Nitrate 400</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-citrulline 3 g</intervention_name>
    <description>Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.</description>
    <arm_group_label>L-citrulline (Aim 1b)</arm_group_label>
    <arm_group_label>Placebo (Aim 1b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil 100 mg</intervention_name>
    <description>Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.</description>
    <arm_group_label>Placebo (Aim 1c)</arm_group_label>
    <arm_group_label>Sildenafil (Aim 1c)</arm_group_label>
    <other_name>Viagra, Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan 125 mg</intervention_name>
    <description>Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.</description>
    <arm_group_label>Bosentan (Aim 2)</arm_group_label>
    <arm_group_label>Placebo (Aim 2)</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-identification of their race and the race of their biological parents as being&#xD;
             only Black (i.e., African American) or only White (i.e., Caucasian American)&#xD;
&#xD;
          -  Born and raised in the United States&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mixed races&#xD;
&#xD;
          -  Any chronic or ongoing disease&#xD;
&#xD;
          -  Prescribed pharmacological treatment&#xD;
&#xD;
          -  Smoking or tobacco use&#xD;
&#xD;
          -  Obesity (body mass index &gt; 30 kg / m2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thales C Barbosa, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thales C Barbosa, Ph.D.</last_name>
    <phone>(601) 984-1468</phone>
    <email>tbarbosa@umc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thales C Barbosa, Ph.D.</last_name>
      <phone>601-984-1468</phone>
      <email>tbarbosa@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Thales C Barbosa, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Barbosa TC, Young BE, Stephens BY, Nandadeva D, Kaur J, Keller DM, Fadel PJ. Functional sympatholysis is preserved in healthy young Black men during rhythmic handgrip exercise. Am J Physiol Regul Integr Comp Physiol. 2020 Sep 1;319(3):R323-R328. doi: 10.1152/ajpregu.00105.2020. Epub 2020 Aug 12.</citation>
    <PMID>32783690</PMID>
  </reference>
  <reference>
    <citation>Barbosa TC, Kaur J, Stephens BY, Akins JD, Keller DM, Brothers RM, Fadel PJ. Attenuated forearm vascular conductance responses to rhythmic handgrip in young African-American compared with Caucasian-American men. Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1316-H1321. doi: 10.1152/ajpheart.00387.2018. Epub 2018 Aug 17.</citation>
    <PMID>30118345</PMID>
  </reference>
  <reference>
    <citation>Kaur J, Barbosa TC, Nandadeva D, Young BE, Stephens BY, Brothers RM, Fadel PJ. Attenuated Rapid-Onset Vasodilation to Forearm Muscle Contraction in Black Men. Med Sci Sports Exerc. 2021 Mar 1;53(3):590-596. doi: 10.1249/MSS.0000000000002511.</citation>
    <PMID>32910095</PMID>
  </reference>
  <reference>
    <citation>Young BE, Kaur J, Vranish JR, Stephens BY, Barbosa TC, Cloud JN, Wang J, Keller DM, Fadel PJ. Augmented resting beat-to-beat blood pressure variability in young, healthy, non-Hispanic black men. Exp Physiol. 2020 Jul;105(7):1102-1110. doi: 10.1113/EP088535. Epub 2020 May 27.</citation>
    <PMID>32362031</PMID>
  </reference>
  <reference>
    <citation>Vranish JR, Holwerda SW, Young BE, Credeur DP, Patik JC, Barbosa TC, Keller DM, Fadel PJ. Exaggerated Vasoconstriction to Spontaneous Bursts of Muscle Sympathetic Nerve Activity in Healthy Young Black Men. Hypertension. 2018 Jan;71(1):192-198. doi: 10.1161/HYPERTENSIONAHA.117.10229. Epub 2017 Dec 4.</citation>
    <PMID>29203629</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Thales Coelho Barbosa</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>Black</keyword>
  <keyword>African American</keyword>
  <keyword>White</keyword>
  <keyword>Caucasian American</keyword>
  <keyword>Hyperemia</keyword>
  <keyword>Blood Flow</keyword>
  <keyword>Conductance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Doppler ultrasound videos, analog-digital recordings, participants' characteristics, and randomization codes will be available in an unidentified format.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>On Jan 1st, 2025 for one year.</ipd_time_frame>
    <ipd_access_criteria>By request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

